公开(公告)号：US20170320824A1

公开(公告)日：2017-11-09

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D209/14 ,  C07D209/12 ,  C07D403/02 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.

公开(公告)号：US20130345214A1

公开(公告)日：2013-12-26

申请号：US13975261

申请日：2013-08-23

Applicant: SRI International, Inc.

Inventor： Ling Jong

IPC: C07D487/04 ,  A61K31/4196 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/407 ,  A61K31/41

CPC classification number: A61K31/407 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/82 ,  C07D487/04 ,  C12Q1/26 ,  G01N2333/90241 ,  G01N2500/04

Abstract: The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.

Abstract translation: 本公开提供了适用于抑制脂氧合酶或Abeta形成的双吲哚，并治疗诸如阿尔茨海默氏病等相关疾病。 双吲哚是吲哚并[2,3-b]咔唑衍生物，并且可以作为药物制剂的一部分施用于患者。

公开(公告)号：US20170095450A1

公开(公告)日：2017-04-06

申请号：US15380548

申请日：2016-12-15

Applicant: SRI International

Inventor： Ling Jong

IPC: A61K31/407 ,  C12Q1/26 ,  A61K31/5377 ,  A61K31/454 ,  A61K45/06 ,  A61K31/4196

CPC classification number: A61K31/407 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/82 ,  C07D487/04 ,  C12Q1/26 ,  G01N2333/90241 ,  G01N2500/04

Abstract: The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.

公开(公告)号：US20230117592A1

公开(公告)日：2023-04-20

申请号：US17788275

申请日：2020-12-18

Applicant: SRI International

Inventor： Ling Jong ,  Nathan Collins ,  Raymond Ng

IPC: C07C217/86 ,  C07C217/92 ,  C07D215/38 ,  C07D213/74 ,  C07D249/08 ,  C07D403/12 ,  C07D401/12 ,  C07D409/12 ,  C07D405/06 ,  C07D209/14 ,  C07C211/53 ,  C07D309/04 ,  C07D305/08 ,  C07D295/13 ,  C07C211/54 ,  C07D413/12 ,  C07D405/12 ,  C07C211/56 ,  C07D403/06 ,  C07D405/14

Abstract: Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

公开(公告)号：US10000451B2

公开(公告)日：2018-06-19

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D403/02 ,  A61K31/404 ,  C07D209/14 ,  C07D209/12 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.

公开(公告)号：US20230174485A1

公开(公告)日：2023-06-08

申请号：US17906885

申请日：2021-03-25

Applicant: SRI International

Inventor： Ling Jong ,  Raymond Ng ,  Nathan Collins

IPC: C07D209/88 ,  C07D403/12 ,  C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D471/22 ,  C07D403/04 ,  C07D405/14 ,  C07D401/12 ,  C07D209/86 ,  C07D223/28

CPC classification number: C07D209/88 ,  C07D403/12 ,  C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D471/22 ,  C07D403/04 ,  C07D405/14 ,  C07D401/12 ,  C07D209/86 ,  C07D223/28

Abstract: Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

公开(公告)号：US10646471B2

公开(公告)日：2020-05-12

申请号：US15380548

申请日：2016-12-15

Applicant: SRI International

Inventor： Ling Jong

IPC: A61K31/407 ,  A61K31/41 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/5377 ,  C07D209/82 ,  A61K31/404 ,  A61K45/06 ,  C07D487/04 ,  C12Q1/26

Abstract: The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.